News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2024 Shelley Wood May 31, 2024
News Daily News EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts Todd Neale April 12, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
Presentation ACC 2024 Main Results From The Step-hfpef Dm Trial Presenter: Mikhail Kosiborod April 06, 2024
News Conference News Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality Michael O'Riordan March 22, 2024
News Daily News Injectable Semaglutide Shortage Forces Physicians to Pivot Todd Neale February 05, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks Todd Neale January 21, 2024
News Daily News FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions Todd Neale January 12, 2024
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News ‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults Michael O'Riordan November 21, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Daily News Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study L.A. McKeown October 10, 2023
News Daily News PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY Michael O'Riordan September 29, 2023
News Daily News GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters Shelley Wood September 28, 2023
News Daily News Half of American Indian and Alaska Native Seniors Have CVD: Medicare Analysis L.A. McKeown September 25, 2023
News Daily News European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba Michael O'Riordan September 15, 2023